The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11149 malaria professionals are enjoying the free benefits of MalariaWorld today

Malaria, IgE, COVID-19, and Vaccines

October 21, 2020 - 00:16 -- Miles Markus

A Blog by Pierre Lutgen in the MalariaWorld Newsletter ( refers to the high overall Immunoglobulin E (IgE) levels that have been found in human populations in areas where malaria is endemic. Further to what is explained in his Blog, but on a different subject:

One of the reasons for IgE production (e.g. Fincham et al., 2007) in malaria-endemic regions is the frequent high prevalence of infection by parasitic worms amongst people living there (e.g. Markus & Fincham, 2000; Markus, 2003). IgE is a marker for the T Helper Cell Type 2 (Th2) immune profile that is associated with helminthiasis, characteristically together with eosinophilia (e.g. Fincham et al., 2003), as well as particular cytokines.

In the absence of deworming, this Th2 scenario can result in a diminished immune response to vaccination against various non-helminthic diseases, possibly including malaria (Markus & Fincham, 2001; Markus & Fincham, 2007).

What the situation will be in relation to future COVID-19 vaccines is currently unknown. If such vaccines do not elicit sufficient protective immunity because of helminthiasis, that will, needless to say, be a problem!



Fincham JE, Markus MB, Adams VJ et al. 2003. Association of deworming with reduced eosinophilia: implications for HIV/AIDS and co-endemic diseases. South African Journal of Science 99: 182–184.


Fincham JE, Markus MB, van der Merwe L et al. 2007. Ascaris, co-infection and allergy: the importance of analysis based on immunological variables rather than egg excretion. Transactions of the Royal Society of Tropical Medicine and Hygiene 101: 680–682.


Markus MB. 2003. Public health and vaccines – immune responses in developed versus poor countries. South African Medical Journal 93: 834–835.


Markus MB, Fincham JE. 2000. Mbeki and AIDS in Africa. Science 288: 2131.


Markus MB, Fincham JE. 2001. Helminthic infection and HIV vaccine trials. Science 291: 46–47.


Markus MB, Fincham JE. 2007. Helminthiasis, bystander diseases and vaccines: analysis of interaction. Trends in Parasitology 23: 517–519.


Submitted by Anonymized User (not verified) on

Indeed, the helminth-associated, potential inhibition of the immune response to vaccination against malaria has been recognized via cited reference number 33 in this publication:

The RTS,S Clinical Trials Partnership. 2014. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Medicine 11: e1001685.

Submitted by Anonymized User (not verified) on

It seems important (see above) to take pre-existing helminth infections (and the absence thereof) into account in malaria vaccine trials in various countries. So far, this matter has generally not received consideration.